Related references
Note: Only part of the references are listed.A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
GOG 3026 A phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study
Brian Slomovitz et al.
GYNECOLOGIC ONCOLOGY (2023)
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen-Shen Lu et al.
CLINICAL CANCER RESEARCH (2022)
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study
Brian M. Slomovitz et al.
GYNECOLOGIC ONCOLOGY (2022)
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Massimo Cristofanilli et al.
CLINICAL CANCER RESEARCH (2022)
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Oaknin et al.
ANNALS OF ONCOLOGY (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
Willem Jan van Weelden et al.
HUMAN PATHOLOGY (2021)
Development of CDK4/6 Inhibitors: A Five Years Update
Alessandra Ammazzalorso et al.
MOLECULES (2021)
Endometrial cancer
Vicky Makker et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
MOLECULAR PROFILING OF NSMP HIGH-RISK ENDOMETRIAL CANCERS OF THE PORTEC-3 TRIAL - PROGNOSTIC REFINEMENT AND DRUGGABLE TARGETS
L. Vermij et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
Kaitlyn J. Andreano et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer
Jing Hu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients: Updated phase II results and dose selection
I. Bulat et al.
ANNALS OF ONCOLOGY (2020)
A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Michela Piezzo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero et al.
ESMO OPEN (2020)
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Qiao Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review
Willem Jan van Weelden et al.
FRONTIERS IN ONCOLOGY (2019)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
Adam M. Brufsky et al.
ONCOLOGIST (2018)
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
David M. Gershenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
John E. Bisi et al.
ONCOTARGET (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2008)